- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07372079
Neoadjuvant terapi för tidig trippelnegativ bröstcancer: Ett responsstyrt tillvägagångssätt med iparomlimab- och tuvonralimab-injektion i kombination med kemoterapi
Neoadjuvant terapi för tidig trippelnegativ bröstcancer: Ett responsstyrt tillvägagångssätt med Iparomlimab och Tuvonralimab-injektion i kombination med kemoterapi
Iparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4). This is a prospective clinical study that plans to enroll screened, eligible early-stage breast-cancer patients to receive neoadjuvant QL1706 plus chemotherapy (four cycles of TP ± four cycles of AC). After the four TP cycles, imaging and core biopsy will be performed. Patients who achieve radiologic complete response will proceed directly to surgery; those who do not will receive four additional AC cycles before surgery. A key feature is the incorporation of an response-guided neoadjuvant therapy(RGN)model to identify sensitive patients who can forgo anthracyclines, thereby reducing long-term cardiotoxicity.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Yongsheng Jia, Doctor
- Telefonnummer: +86 18622199359
- E-post: yongshengjia@tjmuch.com
Studera Kontakt Backup
- Namn: Wenxiao Liu
- Telefonnummer: +86 18515456035
- E-post: liuwenxiao2016@outlook.com
Studieorter
-
-
-
Tianjin, Kina
- Rekrytering
- Tianjin Medical University Cancer Institute & Hospital
-
Kontakt:
- Yongsheng Jia, Doctor
- Telefonnummer: +86 18622199359
- E-post: yongshengjia@tjmuch.com
-
Kontakt:
- Jun Zhang, doctor
- E-post: doctorjunzhang@163.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Voluntarily join this study, sign the informed consent form, and demonstrate good compliance;
- Age: 18-75 years old (at the time of signing the informed consent form);
- ECOG PS score: 0-1; expected survival time exceeding 6 months;
- Patients with primary breast cancer confirmed by histopathological or cytological examination;
- Primary tumor diameter > 2 cm as measured by local standard assessment methods;
- Judged by the investigator to meet the American Joint Committee on Cancer (AJCC) 8th edition breast cancer TNM staging criteria as cT2-cT4, cN0-cN3, cM0, with locally advanced or early-stage, unilateral, and histologically confirmed invasive breast cancer;
- According to the latest ASCO/CAP guideline definitions, histopathologically confirmed early-stage triple-negative invasive breast carcinoma meeting all of the following criteria:Tumors are triple-negative on pathological subtyping, defined as: ER-negative: IHC ≤10%; PR-negative: IHC ≤10%; HER2-negative: IHC 0/1+, or IHC 2+ with negative ISH.
- At least one measurable lesion according to RECIST 1.1;
- The patient agrees to undergo breast cancer resection surgery when meeting the surgical criteria after neoadjuvant therapy;
- PD-L1 expression status is known;
- Major organ functions are in good condition;
- Female subjects of childbearing potential must have a negative serum pregnancy test within 3 days prior to the first dose. If a female subject of childbearing potential engages in sexual activity with a non-sterilized male partner, the subject must use acceptable and effective contraception from screening onward and agree to continue these precautions until 12 months after the last dose of the study drug; periodic abstinence and rhythm methods are not acceptable contraceptive methods.
- The subject is willing to provide core needle biopsy tissue samples for research analysis.
Exclusion Criteria:
- Patients with stage IV metastatic breast cancer or other patients deemed by the investigator as unable to achieve curative surgical resection through neoadjuvant therapy;
- Patients with inflammatory breast cancer;
- Patients who have had or currently have other malignancies within the past 3 years. The following two conditions may be eligible: other malignancies treated with a single surgical procedure, achieving continuous 5-year disease-free survival (DFS); cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)];
- Breast cancer patients who have received antitumor therapies such as chemotherapy, endocrine therapy, or immune checkpoint inhibitors within the past 3 years, or who have undergone breast surgery (except diagnostic biopsy for primary breast cancer);
- Patients who have undergone major surgical treatment, incisional biopsy, or significant traumatic injury within 28 days prior to the start of study treatment (except diagnostic biopsy for primary breast cancer);
- Presence of any active autoimmune disease or a history of autoimmune disease;
- Patients currently using immunosuppressants or systemic hormonal therapy for immunosuppressive purposes (at a dose >10 mg/day prednisone or equivalent steroids) and continuing such treatment within 2 weeks prior to enrollment;
- Allergy to any study drug or any component or excipient of the drug;
- Patients with concomitant diseases judged by the investigator as seriously endangering the subject's safety or affecting study completion, or those deemed unsuitable for enrollment for other reasons.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: QL1706 Combination Therapy
neoadjuvant QL1706 plus chemotherapy (four cycles of TP ± four cycles of AC). |
Participants receive QL1706 every 3 weeks (Q3W) + Albumin-bound paclitaxel every 3 weeks (Q3W) + Cisplatin (Q3W) x 4 cycles. After the four TP cycles, imaging and core biopsy will be performed. Patients who achieve radiologic complete response will proceed directly to surgery; those who do not will receive QL1706 Q3W + epirubicin Q3W + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy before surgery. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
tpCR (ypT0/is ypN0)
Tidsram: Upp till ungefär 27–30 veckor
|
Upp till ungefär 27–30 veckor
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Radiologisk komplett responsfrekvens (iCR)
Tidsram: Upp till cirka 27–30 veckor
|
Upp till cirka 27–30 veckor
|
|
användningsfrekvens för epirubicin-cyklofosfamidregimen
Tidsram: Upp till cirka 16 veckor
|
Upp till cirka 16 veckor
|
|
Händelsefri överlevnad (EFS) enligt bedömning av huvudprövningsläkare
Tidsram: Upp till cirka 8 år
|
Upp till cirka 8 år
|
|
Procentandel av deltagare som upplever en biverkning (AE)
Tidsram: Upp till cirka 60 veckor
|
Upp till cirka 60 veckor
|
|
Övergripande överlevnad (OS)
Tidsram: Upp till cirka 8 år
|
Upp till cirka 8 år
|
|
Poäng för hälsorelaterad livskvalitet (HR-QoL)
Tidsram: Upp till ungefär 27-30 veckor
|
Upp till ungefär 27-30 veckor
|
Samarbetspartners och utredare
Utredare
- Studiestol: Yongsheng Jia, Tianjin Medical University Cancer Institute and Hospital
- Huvudutredare: Jun Zhang, Tianjin Medical University Cancer Institute and Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- E20251311
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .